Kidney cancer is one of the 10 most common cancers both in the United States and worldwide. Until this year, there had not previously been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. Therefore, a group of researchers, clinicians, and patient advocates dedicated to renal cell carcinoma launched the Kidney Cancer Research Summit (KCRS) to spur collaboration and further therapeutic advances in these tumors. This commentary aims to summarize the oral presentations and serve as a record for future iterations of this meeting. The KCRS sessions addressed the tumor microenvironment, novel methods of drug delivery, single cell sequencing strategies, novel immune checkpoint blockade and cellular therapies, predictive biomarkers, and rare variants of kidney cancers. In addition, the meeting included 2 sessions to promote scientific mentoring and kidney cancer research collaborations. A subsequent KCRS will be planned for the fall of 2020.

中文翻译：

---

2019 年 9 月 12-13 日首届肾癌研究峰会摘要：聚焦转化研究

肾癌是美国和全世界最常见的 10 种癌症之一。直到今年，之前还没有一个会议专注于广泛和异质性肾癌组的转化研究。因此，一群致力于肾细胞癌的研究人员、临床医生和患者倡导者发起了肾癌研究峰会 (KCRS)，以促进这些肿瘤的合作和进一步的治疗进展。本评论旨在总结口头陈述，并作为本次会议未来迭代的记录。KCRS 会议讨论了肿瘤微环境、新型药物递送方法、单细胞测序策略、新型免疫检查点阻断和细胞疗法、预测性生物标志物以及肾癌的罕见变异。此外，会议包括两场会议，以促进科学指导和肾癌研究合作。随后的 KCRS 计划于 2020 年秋季进行。